Changes in Hong Kong stocks | Xianjian Technology (01302) rose more than 3% Recently, the Yuranos Plus abdominal aortic laminating stent system was approved for listing by NMPA

The Zhitong Finance App learned that Xianjian Technology (01302) rose more than 3%. As of press release, it had risen 2.27% to HK$1.35, with a turnover of HK$19.5463 million.

According to news, recently, according to Xianjian Technology's WeChat account, the company's self-developed Yuranos Plus abdominal aortic stent system (Yuranos Plus) has been registered and approved by the National Drug Administration (NMPA) and officially entered the Chinese market. Yuranos Plus has been fully upgraded on the basis of the Yuranos abdominal aortic laminating stent system. It is suitable for intracavitary treatment of subrenal abdominal aortic aneurysms. In particular, it provides a better minimally invasive intervention solution for patients with complex neck anatomy and narrowing of blood vessels in the pathway.